Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of VX-121/TEZ/D-IVA in Cystic Fibrosis
2024-514173-22-00Phase 3Authorised
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, open-label trial of adapalene + clindamycin in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Safety and tolerability of long-term treatment with VX-121/TEZ/D-IVA. Planned start Jun 2024; status: authorised.
02
Drugs
adapalene + clindamycin
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2024-514173-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514173-22-00.